Zilai Zhang,1 Jinhui Wang,1 Weiguo Zou,1 Binghua Li,1 Zifei Pei,1 Jinfa Gu,1 Cheng Qian,2 Xinyuan Liu.1 1Institute of Biochemistry and Cell Biology,Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, Shanghai, China; 2Medicine, Medical School, University of Navarra, Pamplona, Spain. Armed oncolytic adenoviruses represent an appealing tumor treatment. In this paper, considing that angiogenesis play an important role in tumor growth, the antiangiogenic gene, sflt-1(1-3) (the first three extracellular domain of hVEGF receptor) was inserted into ZD55 (an E1B55-kD deleted oncolytic adenovirus previously constructed in our lab) to form ZD55-sflt-1. ZD55-sflt-1 could specifically induce cytopathic effect in tumor cells in vitro. The expression of sFLT-1 from ZD55-sflt-1 was much higher than that of replication–deficient Ad-sflt-1, which contributed to its stronger inhibitory effect of VEGF-induced HUVEC proliferation (35.4386% of control). Furthermore, a marked reduction of tumor growth was observed in ZD55-sflt-1-treated nude mice with subcutaneous human SW620 colon tumor. Its efficacy directly corrected with a decrease in microvessel density and an increase in apoptosis of tumor cells. A much more efficient antitumoral effect was obtained when ZD55-sflt-1 was combined with ZD55-trail (another oncolytic adenovirus engineered to express the tumor necrosis factor-related apoptosis-inducing ligand), which resulted in 57.14% complete tumor regression and 71.43% prolonged survival of mice. These results indicate that ZD55-sflt-1, which combines the advantages of oncolytic adenovirus and the antiangiogenic gene system, can result in a striking improvement in treatment efficacy, and is suitable for synergistic therapy with other agents.